PURPOSE: The objective of this study was to determine optimal aerosol delivery conditions for a full-term (3.6 kg) infant receiving invasive mechanical ventilation by evaluating the effects of aerosol particle size, a new wye connector, and timing of aerosol delivery. METHODS: In vitro experiments used a vibrating mesh nebulizer and evaluated drug deposition fraction and emitted dose through ventilation circuits containing either a commercial (CM) or new streamlined (SL) wye connector and 3-mm endotracheal tube (ETT) for aerosols with mass median aerodynamic diameters of 880 nm, 1.78 μm, and 4.9 μm. The aerosol was released into the circuit either over the full inhalation cycle (T1 delivery) or over the first half of inhalation (T2 delivery). Validated computational fluid dynamics (CFD) simulations and whole-lung model predictions were used to assess lung deposition and exhaled dose during cyclic ventilation. RESULTS: In vitro experiments at a steady-state tracheal flow rate of 5 L/min resulted in 80-90% transmission of the 880-nm and 1.78-μm aerosols from the ETT. Based on CFD simulations with cyclic ventilation, the SL wye design reduced depositional losses in the wye by a factor of approximately 2-4 and improved lung delivery efficiencies by a factor of approximately 2 compared with the CM device. Delivery of the aerosol over the first half of the inspiratory cycle (T2) reduced exhaled dose from the ventilation circuit by a factor of 4 compared with T1 delivery. Optimal lung deposition was achieved with the SL wye connector and T2 delivery, resulting in 45% and 60% lung deposition for optimal polydisperse (∼1.78 μm) and monodisperse (∼2.5 μm) particle sizes, respectively. CONCLUSIONS: Optimization of selected factors and use of a new SL wye connector can substantially increase the lung delivery efficiency of medical aerosols to infants from current values of <1-10% to a range of 45-60%.
PURPOSE: The objective of this study was to determine optimal aerosol delivery conditions for a full-term (3.6 kg) infant receiving invasive mechanical ventilation by evaluating the effects of aerosol particle size, a new wye connector, and timing of aerosol delivery. METHODS: In vitro experiments used a vibrating mesh nebulizer and evaluated drug deposition fraction and emitted dose through ventilation circuits containing either a commercial (CM) or new streamlined (SL) wye connector and 3-mm endotracheal tube (ETT) for aerosols with mass median aerodynamic diameters of 880 nm, 1.78 μm, and 4.9 μm. The aerosol was released into the circuit either over the full inhalation cycle (T1 delivery) or over the first half of inhalation (T2 delivery). Validated computational fluid dynamics (CFD) simulations and whole-lung model predictions were used to assess lung deposition and exhaled dose during cyclic ventilation. RESULTS: In vitro experiments at a steady-state tracheal flow rate of 5 L/min resulted in 80-90% transmission of the 880-nm and 1.78-μm aerosols from the ETT. Based on CFD simulations with cyclic ventilation, the SL wye design reduced depositional losses in the wye by a factor of approximately 2-4 and improved lung delivery efficiencies by a factor of approximately 2 compared with the CM device. Delivery of the aerosol over the first half of the inspiratory cycle (T2) reduced exhaled dose from the ventilation circuit by a factor of 4 compared with T1 delivery. Optimal lung deposition was achieved with the SL wye connector and T2 delivery, resulting in 45% and 60% lung deposition for optimal polydisperse (∼1.78 μm) and monodisperse (∼2.5 μm) particle sizes, respectively. CONCLUSIONS: Optimization of selected factors and use of a new SL wye connector can substantially increase the lung delivery efficiency of medical aerosols to infants from current values of <1-10% to a range of 45-60%.
Entities:
Keywords:
CFD simulations; Monte Carlo modeling; aerosols; mechanical ventilation; nebulization; neonate; respiratory drug delivery; streamlined wye
Authors: Jean C Dubus; Laurent Vecellio; Michele De Monte; James B Fink; Daniel Grimbert; Jerome Montharu; Chantal Valat; Neil Behan; Patrice Diot Journal: Pediatr Res Date: 2005-03-17 Impact factor: 3.756
Authors: Dorisanne D Miller; Mohammad M Amin; Lucy B Palmer; Akbar R Shah; Gerald C Smaldone Journal: Am J Respir Crit Care Med Date: 2003-07-31 Impact factor: 21.405
Authors: Jan Mazela; Krzysztof Chmura; Maksymilian Kulza; Christopher Henderson; Timothy J Gregory; Arkadiusz Moskal; Tomasz R Sosnowski; Ewa Florek; Lucyna Kramer; Martin Keszler Journal: J Aerosol Med Pulm Drug Deliv Date: 2013-03-19 Impact factor: 2.849
Authors: Karl Bass; Susan Boc; Michael Hindle; Kelley Dodson; Worth Longest Journal: J Aerosol Med Pulm Drug Deliv Date: 2018-12-15 Impact factor: 2.849
Authors: P Worth Longest; Karl Bass; Rabijit Dutta; Vijaya Rani; Morgan L Thomas; Ahmad El-Achwah; Michael Hindle Journal: Expert Opin Drug Deliv Date: 2018-12-10 Impact factor: 6.648
Authors: Connor Howe; Mohammad A M Momin; Dale R Farkas; Serena Bonasera; Michael Hindle; P Worth Longest Journal: Pharm Res Date: 2021-08-30 Impact factor: 4.580
Authors: Felix C Wiegandt; Ulrich P Froriep; Fabian Müller; Theodor Doll; Andreas Dietzel; Gerhard Pohlmann Journal: Pharmaceutics Date: 2021-05-04 Impact factor: 6.321
Authors: Felix C Wiegandt; David Biegger; Jacob F Fast; Grzegorz Matusiak; Jan Mazela; Tobias Ortmaier; Theodor Doll; Andreas Dietzel; Bettina Bohnhorst; Gerhard Pohlmann Journal: Pharmaceutics Date: 2021-05-14 Impact factor: 6.321